ActualitéPour les professionnels de la santé
Dr Reddy's Laboratories obtient l'autorisation réglementaire du DCGI pour Zytorvi (toripalimab)
Dr Reddy's Laboratories has obtained regulatory approval from India's Drugs Controller General for Zytorvi (toripalimab), a monoclonal antibody targeting PD-1. The drug is approved as first-line treatment in combination with cisplatin and paclitaxel for adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma, which accounts for approximately 80% of oesophageal cancer cases in India. In clinical analysis, median overall survival with toripalimab plus chemotherapy was 17.7 months compared with 12.9 months for chemotherapy alone.
Patients in India with advanced oesophageal squamous cell carcinoma now have access to an immunotherapy option that extends median survival by nearly five months when combined with standard chemotherapy.
Voir aussi
Autres sources
- ActualitéCarcinome du nasopharynx : le toripalimab disponible en accès direct
- ActualitéCarcinome du nasopharynx récidivant ou métastatique : 1ère thérapie ciblée désormais disponibleLes patients atteints d'un carcinome du nasopharynx métastatique ou récidivant non opérables ont accès à une première thérapie ciblée approuvée en première ligne.